Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NO CURRENT FORECAST
Last analysis on September 14, 2026; a refreshed forecast appears once the daily run covers this ticker again.

Apogee Therapeutics, Inc. (APGE) AI Forecast

The forecast for Apogee Therapeutics, Inc. has not been refreshed recently; create a free account and follow it to be notified when a new one is published.

✓ Free account • ✓ 30-day free trial

$APGE No current forecast Full forecast available
Sign Up Free

Apogee Therapeutics, Inc. (APGE) Stock Forecast Sept. 14, 2026

Apogee Therapeutics, Inc. (APGE) AI Stock Price Forecast & Investment Analysis

This forecast was produced 5 trading days ago and has not been refreshed since; read it as historical, not as a current view.

Apogee Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Apogee Therapeutics, Inc. (APGE) - Comprehensive Stock Analysis & Investment Research

Deep dive into Apogee Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 14, 2026 (UTC)

Apogee Therapeutics, Inc. Investment Summary

When evaluating whether Apogee Therapeutics, Inc. (APGE) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Apogee Therapeutics, Inc. (APGE) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $10 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Apogee Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Apogee Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Apogee Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Apogee Therapeutics, Inc.

Sign Up Free
Corporate Identity

Apogee Therapeutics, Inc. (Stock Symbol: APGE) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Apogee Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Apogee Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Apogee Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Apogee Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Apogee Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Apogee Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Apogee Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Apogee Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Apogee Therapeutics, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Apogee Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Apogee Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 26.44 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Apogee Therapeutics, Inc. (APGE) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Apogee Therapeutics, Inc. stock analysis.

Deep dive into Apogee Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Apogee Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Apogee Therapeutics, Inc.:

Market Cap $10.22B
EPS $-4.33
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Apogee Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Apogee Therapeutics, Inc.:

ROA -21.2%
ROIC -23.5%
Tax Rate -0.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Apogee Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Apogee Therapeutics, Inc.: A current ratio of 26.44 indicates strong liquidity.

Current Ratio 26.44x
Working Capital $954M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Apogee Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Apogee Therapeutics, Inc.:

Operating Cash Flow -$235M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Apogee Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Apogee Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Apogee Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Apogee Therapeutics, Inc.:

Income Statement
Operating Income -$305M
Net Income -$282M
R&D Expense $229M
Balance Sheet Highlights (USD millions)
Total Current Assets $992M
Cash & Short-term Investments $106M
Total Liabilities $141M
Short-term Debt $34M
Dividend & Shareholder Information
Shares Outstanding 76M

Latest Apogee Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Apogee Therapeutics, Inc. (APGE) stock price and investment outlook.

📰 Loading...

Where APGE sits on the market map

Explore the map →

Apogee Therapeutics, Inc. Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Apogee Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
APGE ██% $10.22B x x
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
IMVT ██% $7.63B x 10.4x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
DNLI ██% $3.27B x 3.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
CGEM ██% $1.37B x 4.3x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
REPL ██% $1.23B x 11.7x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
ALLO ██% $584M x 1.3x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Apogee Therapeutics, Inc. Stock Forecast

How accurate are Apogee Therapeutics, Inc. stock predictions?

A per-ticker accuracy statistic for APGE is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Apogee Therapeutics, Inc. stock price forecasts?

Our analysis considers Apogee Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Apogee Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Apogee Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Apogee Therapeutics, Inc. forecasts updated?

Apogee Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 14, 2026.

Want a simpler view of Apogee Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...